Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines do not readily address.
For more information, please visit the Senti Bio website at https://www.sentibio.com.
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $158M
Founded date: 2016
Investors 9
Funding Rounds 2
| Date | Series | Amount | Investors |
| 06.01.2021 | - | $105M | - |
| 27.02.2018 | Series A | $53M | New Enterp... |
Mentions in press and media 9
| Date | Title | Description | Source |
| 20.12.2021 | Senti Bio and Dynamics Special Purpose Corp. Announce Busine... | - Business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS) is expected to provide mor... | marketscre... |
| 20.12.2021 | Dynamics Special Purpose : Senti Bio and Dynamics Special Pu... | Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publi... | marketscre... |
| 06.01.2021 | Senti Bio raises $105 million for its new programmable biolo... | Senti Biosciences, a company developing cancer therapies using a new programmable biology platform, ... | techcrunch... |
| 27.02.2018 | Senti Biosciences Secures $53M in Series A Funding | Senti Biosciences, a South San Francisco, Calif.-based the synthetic biology company developing adap... | finsmes.co... |
| 27.02.2018 | Amgen Ventures Backs Senti Biosciences In $53M Funding ... | Amgen Ventures, the venture capital arm of Amgen, is one of the investors in synthetic biology start... | socaltech.... |
| 27.02.2018 | All-star team of synthetic biologists raise $53 million for ... | A who’s-who from the world of synthetic biological research have come together to launch Senti Biosc... | techcrunch... |
| 27.02.2018 | NEA Leads $53M Round for Senti Biosciences | Senti Biosciences, the synthetic biology company developing next-generation adaptive therapies for i... | citybizlis... |
| 27.02.2018 | Senti Biosciences Receives $53M | SAN FRANCISCO, CA, Senti Biosciences today announced the completion of a $53 million round of fund... | vcnewsdail... |
| 27.02.2018 | Term Sheet — Tuesday, February 27 | CO-WORKING WARS Good morning, Term Sheet readers. Paid Content How can you protect what you can't se... | fortune.co... |